Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULTIMATE: Paclitaxel-Bevacizumab vs Docetaxel in NSCLC
NCT01763671Phase 3Completed
- Sponsor
- IFCT
- Start
- May 2013
- Primary completion
- Dec 2015
- Modality
- Cytokines & Interferons, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Paclitaxel Micelles for Injection and bevacizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by IFCT. Primary endpoint: Progression Free Survival at 4 months. Started May 2013; status: completed.
02
Drugs
Paclitaxel Micelles for Injectionbevacizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT01763671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01763671.